Latest Conference

Uncovering interesting findings regarding patients' PrEP regimen.

How much does the current virus crisis share in common with early HIV outbreak scare?

Time interval goes down by 3 months in 3 year period.

Investigators compared characteristics and retention between daily and event-driven PrEP patients to better understand low uptake of event-driven PrEP.

Experts assessed the impact of drug overdoses on people living with HIV in British Columbia, identifying factors associated with mortality using competing risk methodology.

People with HIV are living longer than ever at present time, raising quality of life concerns about later stage medical and psychological challenges comorbidities.

Small study shows HIV patients not at a greater risk for worse outcomes.

The California PrEP Assistance Program, established to remove financial and structural barriers to PrEP access, had positive but uneven initial results.

With fostemsavir now available for patients with few options, an expert discusses what challenges MDR-HIV patients face in their care.

A 34-year-old Brazilian man's HIV was undetectable 57 weeks after ending a heightened regimen of ART.

A look at the BRIGHTE study data which evidenced the recently FDA-approved add-on agent.

In low-level HIV-1 viraemia patients, this strategy demonstrated viral suppression in more than half of a study's participants.

Despite being recommended at least once among all persons aged 13-64 years old by the CDC, notably few respondents have ever been tested for HIV.

Guidelines recommend concentrated adherence counseling and frequent viral load testing for virologic failure, but drug resistance testing is often excluded.

Interim analysis shows a long-acting injectable was associated with fewer HIV infections than daily oral PrEP in a diverse population of HIV-risk participants.

A retrospective analysis of the DRIVE-FORWARD and DRIVE-AHEAD trials shows treatment-naive patients particularly fared well from the novel agent.

Carey Hwang, MD, PhD, executive director and product development lead, Global Clinical Development of Infectious Disease at Merck spoke with Contagion® regarding the therapies and went further into depth about the studies.

A report released for AIDS 2020 warns the international AIDS response could be set back substantially by ongoing events.

CUSTOMIZE was designed to identify methods of implementing an experimental once-monthly, long-acting regimen antiretroviral therapy against HIV-1 into clinical practice.

The antibacterial is efficacious in a majority of patients in a small study.

Antimicrobial stewardship education was conducted with de-identified provider-specific prescribing scorecards.

A dosage of 250 mg twice daily for 10 days was confirmed for the next phase of trials after achieving initial and sustained cure in 100% of patients.

The novel drug combines a fourth-generation cephalosporin with a novel extended-spectrum β-lactamase inhibitor.

Drug resistance has physicians racing to find alternative therapies for many infections. In a new non-inferiority study, fosfomycin was inferior to more common therapies.

Gram-negative bacteria can cause infections, are resistant to multiple drugs, and are increasingly resistant to most available antibiotics, the CDC says.

Oral ibrexafungerp could cut hospital stays for patients with invasive candidiasis infections.

It is known that the type of respiratory specimen, sampling environmental factors, and time from symptom onset impact the sensitivity of rapid influenza diagnostic tests.

Investigators say they consider cefiderocol a candidate for therapeutic drug monitoring.